PHARMACEUTICAL 2025

Bristol Myers Squibb CO
Rank 130 of 225



PHARMACEUTICAL 2025

Bristol Myers Squibb CO
Rank 130 of 225

The relative strengths and weaknesses of Bristol Myers Squibb CO are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bristol Myers Squibb CO compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 36% points.The greatest weakness of Bristol Myers Squibb CO is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 115% points.

The company's Economic Capital Ratio, given in the ranking table, is 172%, being 43% points below the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	29,780,000
Cost of Goods Sold	13,968,000
Intangible Assets	45,026,000
Liabilities, Current	23,774,000
Liabilities, Non-Current	52,072,000
Other Assets	10,661,000
Other Compr. Net Income	293,000
Other Expenses	23,692,000
Other Liabilities	369,000
Other Net Income	0
Other Revenues	48,300,000
Property and Equipment	7,136,000
Research and Development	11,159,000
Selling, General and Administrative Expense	8,414,000

Output Variable	Value in 1000 USD
Assets	92,603,000
Liabilities	76,215,000
Expenses	57,233,000
Revenues	48,300,000
Stockholders Equity	16,388,000
Net Income	-8,933,000
Comprehensive Net Income	-8,786,500
BaseVar	137,322,000
ECR before LimitedLiability	32%
Economic Capital Ratio	172%